The Market Access Special Forces

As partners of our internationally operating clients, we support the successful market access especially of treatments for rare diseases, of ATMPs or of products which set new therapy standards, both on a strategic and operational level.
One HTA to assess them all

The SKC whitepaper analyzes the implications of the EU HTA framework and derives operative, strategic, and structural success factors to optimally prepare and handle the new process.
Market access for gene therapies

Our exclusive white paper provides a comprehensive analysis to derive key considerations for the strategic challenges for gene therapies in Germany, with a focus on pricing and reimbursement
The EU HTA scoping process: a puzzle to be solved

SKC simulation of the expected PICO schemes on EU Big 6
Digital Health Applications (DiGAs)

With our longstanding AMNOG-expertise we support DiGA-providers with a customized market access strategy – all the way from the development of the value story to successful price negotiations.
Creating value in health care

"A unique combination of deep understanding of the matter, strategic vision, didactic skill and humor."

Founder and CEO of medical-technology company

to the top